Brought to you by 
Series B brings in $43mm for CNS start-up NeuroTherapeutics
21 May 2010
Executive Summary
First-time investors MPM Capital and SR One have co-led the $43mm Series B financing for NeuroTherapeutics Pharma Inc. (diseases caused by a hyperexcitable central nervous system). Fidelity Biosciences and Pfizer Venture Investments, other new backers, also participated along with returning shareholders Novo Ventures and Thomas McNerney & Partners. All of the new investors have contributed board members to the company.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Series B brings in $43mm for CNS start-up NeuroTherapeutics
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice